NASDAQ:ANIK - Anika Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$35.67 +0.09 (+0.25 %)
(As of 01/23/2019 04:00 PM ET)
Previous Close$35.58
Today's Range$34.5150 - $35.99
52-Week Range$28.54 - $69.81
Volume63,378 shs
Average Volume144,979 shs
Market Capitalization$506.91 million
P/E Ratio18.20
Dividend YieldN/A
Beta1.59
Anika Therapeutics, Inc., together with its subsidiaries, provides orthopedic medicines for patients with degenerative orthopedic diseases and traumatic conditions in the United States and internationally. The company develops, manufactures, and commercializes therapeutic products based on its proprietary hyaluronic acid (HA) technology. Its orthobiologics products comprise ORTHOVISC, ORTHOVISC mini, MONOVISC, and CINGAL for the treatment of osteoarthritis of the knee; HYALOFAST, a biodegradable support for human bone marrow mesenchymal stem cells used for cartilage regeneration and as an adjunct for microfracture surgery; HYALONECT, a resorbable knitted fabric mesh; HYALOSS used to mix blood/bone grafts to form a paste for bone regeneration; and HYALOGLIDE, an ACP gel used in tenolysis treatment. The company's dermal products include wound care products that comprise HYALOMATRIX and HYALOFILL for the treatment of complex wounds, such as burns and ulcers, and for use in connection with the regeneration of skin; and ELEVESS, an aesthetic dermatology product. Its surgical products comprise HYALOBARRIER, a post-operative adhesion barrier for use in the abdomino-pelvic area; INCERT, a HA product used for the prevention of post-surgical spinal adhesions; MEROGEL, a woven fleece nasal packing; and MEROGEL INJECTABLE, a viscous hydrogel. The company also offers ophthalmic products, including injectable HA products that are used as viscoelastic agents in ophthalmic surgical procedures, such as cataract extraction and intraocular lens implantation; and veterinary products, which include HYVISC, an injectable HA product for the treatment of joint dysfunction in horses. Anika Therapeutics, Inc. has a strategic collaboration with the Institute for Applied Life Sciences at the University of Massachusetts Amherst to develop a therapy for rheumatoid arthritis. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.

Receive ANIK News and Ratings via Email

Sign-up to receive the latest news and ratings for ANIK and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Supplies
SectorMedical
Current SymbolNASDAQ:ANIK
CUSIP03525510
Phone781-457-9000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$113.42 million
Cash Flow$2.3298 per share
Book Value$17.97 per share

Profitability

Net Income$31.81 million

Miscellaneous

Employees123
Market Cap$506.91 million
OptionableOptionable

Anika Therapeutics (NASDAQ:ANIK) Frequently Asked Questions

What is Anika Therapeutics' stock symbol?

Anika Therapeutics trades on the NASDAQ under the ticker symbol "ANIK."

How were Anika Therapeutics' earnings last quarter?

Anika Therapeutics Inc (NASDAQ:ANIK) announced its quarterly earnings results on Wednesday, October, 24th. The biotechnology company reported $0.53 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.31 by $0.22. The biotechnology company earned $26.79 million during the quarter, compared to analysts' expectations of $27.12 million. Anika Therapeutics had a net margin of 17.66% and a return on equity of 9.78%. The company's revenue was down 1.4% on a year-over-year basis. During the same period in the prior year, the company posted $0.46 EPS. View Anika Therapeutics' Earnings History.

When is Anika Therapeutics' next earnings date?

Anika Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, February 20th 2019. View Earnings Estimates for Anika Therapeutics.

What price target have analysts set for ANIK?

3 brokers have issued 12-month target prices for Anika Therapeutics' shares. Their forecasts range from $34.00 to $48.00. On average, they anticipate Anika Therapeutics' share price to reach $41.00 in the next twelve months. This suggests a possible upside of 14.9% from the stock's current price. View Analyst Price Targets for Anika Therapeutics.

What is the consensus analysts' recommendation for Anika Therapeutics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Anika Therapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Anika Therapeutics.

Has Anika Therapeutics been receiving favorable news coverage?

News stories about ANIK stock have trended negative this week, InfoTrie reports. The research firm scores the sentiment of news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Anika Therapeutics earned a news sentiment score of -2.0 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 2.0 out of 10, indicating that recent news coverage is very unlikely to have an effect on the stock's share price in the near future.

Who are some of Anika Therapeutics' key competitors?

Who are Anika Therapeutics' key executives?

Anika Therapeutics' management team includes the folowing people:
  • Mr. Joseph G. Darling, CEO, Pres & Director (Age 61)
  • Ms. Sylvia Cheung, CFO, Treasurer & Sec. (Age 44)
  • Dr. Edward S. Ahn, Chief Technology & Strategy Officer (Age 47)
  • Mr. Richard Hague, Chief Commercial Officer (Age 59)
  • Mr. Alexei Goraltchouk, VP of Operations

Who are Anika Therapeutics' major shareholders?

Anika Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include BTIM Corp. (1.76%), Assenagon Asset Management S.A. (0.40%) and Nisa Investment Advisors LLC (0.01%). Company insiders that own Anika Therapeutics stock include Charles H Sherwood, Jeffery S Thompson and Richard Hague. View Institutional Ownership Trends for Anika Therapeutics.

Which institutional investors are selling Anika Therapeutics stock?

ANIK stock was sold by a variety of institutional investors in the last quarter, including Nisa Investment Advisors LLC. View Insider Buying and Selling for Anika Therapeutics.

Which institutional investors are buying Anika Therapeutics stock?

ANIK stock was bought by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A. and BTIM Corp.. View Insider Buying and Selling for Anika Therapeutics.

How do I buy shares of Anika Therapeutics?

Shares of ANIK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Anika Therapeutics' stock price today?

One share of ANIK stock can currently be purchased for approximately $35.67.

How big of a company is Anika Therapeutics?

Anika Therapeutics has a market capitalization of $506.91 million and generates $113.42 million in revenue each year. The biotechnology company earns $31.81 million in net income (profit) each year or $1.96 on an earnings per share basis. Anika Therapeutics employs 123 workers across the globe.

What is Anika Therapeutics' official website?

The official website for Anika Therapeutics is http://www.anikatherapeutics.com.

How can I contact Anika Therapeutics?

Anika Therapeutics' mailing address is 32 WIGGINS AVENUE, BEDFORD MA, 01730. The biotechnology company can be reached via phone at 781-457-9000 or via email at [email protected]


MarketBeat Community Rating for Anika Therapeutics (NASDAQ ANIK)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  196 (Vote Outperform)
Underperform Votes:  177 (Vote Underperform)
Total Votes:  373
MarketBeat's community ratings are surveys of what our community members think about Anika Therapeutics and other stocks. Vote "Outperform" if you believe ANIK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ANIK will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/23/2019 by MarketBeat.com Staff

Featured Article: Dividend Aristocrat Index

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel